Login to Your Account

Other News To Note

Tuesday, November 29, 2011
• Galena Biopharma Inc., of Lake Oswego, Ore., entered a clinical development collaboration with Genentech Inc., of South San Francisco, and the Henry M. Jackson Foundation for the Advancement of Military Medicine to develop NeuVax (E75) in combination with Genentech's Herceptin (trastuzumab) in adjuvant breast cancer patients currently not eligible for Herceptin therapy. Genentech and Galena will sponsor a randomized, blinded multicenter Phase II study in adjuvant breast cancer in about 300 subjects.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription